Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Jorn BrouwerVincent J NijenhuisRonak DelewiRenicus S HermanidesWouter HolvoetChristophe L F DuboisPeter FrambachBernard De BruyneGert K van HouwelingenJan A S Van Der HeydenPetr ToušekFrank van der KleyIan BuysschaertCarl E SchotborghBert FerdinandePim van der HarstJohn RoosenJoyce PeperFrederick W F ThielenLeo VeenstraDean R P P Chan Pin YinMartin J SwaansBenno J W M RensingArnoud W J van 't HofLeo TimmersJohannes C KelderPieter R StellaJan BaanJurriën M Ten BergPublished in: The New England journal of medicine (2020)
Among patients undergoing TAVI who did not have an indication for oral anticoagulation, the incidence of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less frequent with aspirin than with aspirin plus clopidogrel administered for 3 months. (Funded by the Netherlands Organization for Health Research and Development; POPular TAVI EU Clinical Trials Register number, 2013-003125-28; ClinicalTrials.gov number, NCT02247128.).
Keyphrases
- transcatheter aortic valve implantation
- antiplatelet therapy
- atrial fibrillation
- low dose
- percutaneous coronary intervention
- aortic valve
- acute coronary syndrome
- aortic valve replacement
- aortic stenosis
- patients undergoing
- clinical trial
- cardiovascular events
- transcatheter aortic valve replacement
- coronary artery disease
- ejection fraction
- risk factors
- venous thromboembolism
- anti inflammatory drugs
- heart failure
- cardiovascular disease
- left ventricular
- phase ii